GlobeNewswire

Toronto Wolfpack Partners With International Cannabis and Organic Flower to Release CBD-Infused Topical Cream ‘Rugby Strength’

Share

TORONTO, May 12, 2019 (GLOBE NEWSWIRE) -- Toronto Wolfpack RLFC (“Toronto Wolfpack”) is set to become the first professional sporting team to enter the thriving CBD-infused products marketplace. Toronto Wolfpack and its 100% owned subsidiary HowlBrands Inc. have entered into a definitive agreement with ICC International Cannabis Corp. (CSE: WRLD.U)(FWB:8K51)(OTC: WLDCF) and Organic Flower Investments Group Inc. (CSE: SOW)(FWB:2K6)(OTC: QILFF) to launch a suite of athlete-focused cannabidiol products to market.

Toronto Wolfpack and HowlBrands plan to release their inaugural CBD-infused topical cream, ‘Rugby Strength’, in the coming months. Rugby Strength is custom-formulated to combat acute aches and pains and absorbs quickly to deliver strong and deep-seated relief. It is made with full-spectrum CBD extract from 100% organically grown hemp and blend of natural ingredients, containing zero THC and therefore has no psychoactive effects.

This new venture sees the Wolfpack stepping into the CBD market that has been estimated to reach US$22 billion by 2022, while looking to modernise the way not just athletes but everyone deals with pain.

HowlBrands
HowlBrands is a branding and product development company at the nexus of sports and wellness with a special focus on CBD. David Argyle, Chairman of the Toronto Wolfpack spoke regarding the unprecedented venture:

“HowlBrands aims to interact with consumers within, across and beyond rugby and sports. In the same way that one does not have to be an athlete or play sports to wear Nike shoes, one does not have to be an athlete or play sports to use Rugby Strength or other HowlBrands products. Anyone who experiences pain, soreness or physical discomfort can use Rugby Strength.”

Eva Allouche, Head of Global Brands for HowlBrands, discussed the goal of the partner-ship:

“Our goal is to bridge the gap between professional sports and CBD to offer athletes, active people and anyone who experiences physical discomfort, a range of unique wellness products that deliver the indisputable therapeutic benefits of hemp-based CBD. HowlBrands is about more than offering a pain solution for athletes and active people, it is about deepening the meaning of wellness through brands that open up the discourse around holistic approaches to taking proper care of ourselves. HowlBrands is about enriching the lives of people.”

Go-To-Market Strategy
HowlBrands launch strategy will be executed online in the US and UK and will leverage an expansive distribution network of 80,000 retail outlets and pharmacies as well as GMP certified facilities.
International Cannabis and Organic Flower are critical to a worldwide distribution plan that will see several CBD-infused product lines becoming available through HowlBrands. This includes topical creams, therapeutic relief balms, sport pain tinctures, soaks and roll-ons, all uniquely engineered to be fast-absorbing and deeply penetrating.
In line with the core values of the Toronto Wolfpack, a portion of the proceeds from Rugby Strength will be reinvested into the development of rugby around the world.

Manufacturing
All HowlBrands products, including Rugby Strength, are developed and formulated by a team of medical professionals and natural health experts and are manufactured with THC-free, CBD extract from organically grown hemp. Our manufacturing partners comply with the industry’s highest standards and provide full, batch-specific documentation. All results are corroborated by rigorous third-party testing and all our products come with THC-free, non-GMO, gluten free, vegan and organic accreditation.

About the Wolfpack
Toronto Wolfpack are a professional Rugby team dedicated to progressing through the Rugby League Football's ranks, from League 1 to the Super League. We are the first North American team to play in the RFL and the world’s first transatlantic professional sports team. The Wolfpack organization is driven by the belief that the world is a better place with more rugby balls in kids’ hands. We also aspire to create a global centre for rugby excellence in Toronto, to showcase the best of Ontario by supporting family run local businesses and to actively promote transatlantic trade between North American and UK partners.

Toronto Wolfpack’s impressive and ever-growing media profile includes a broadcast reach to over 140 million homes, in-stadium attendances of up to 9,500 fans at home games during the RFL Championship, highly acclaimed game day experience and a social media presence of over 100,000 verified followers has seen the Club grown from strength to strength each year.

Currently sitting at the top of the RFL Championship table with a record of 12-1 in a league boasting teams from the UK, France and Canada, the Wolfpack have their sights firmly set on achieving the goal of Super League promotion for the 2020 season.

Learn more about Howl’s product range at: www.howlbrands.com

Learn more about the Toronto Wolfpack at: www.torontowolfpack.com
Twitter: @TOwolfpack
Instagram: torontowolfpackofficial
Facebook: TorontoWolfpack

For media inquiries, please contact:
Erik Grosman +1 (647) 204-9655 / erik.grosman@torontowolfpack.com
Martin Vickers +44 7808 556315 / martin@torontowolfpack.com

Notice Regarding Forward Looking Information:
This news release contains certain "forward-looking information" within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or information that certain events or conditions "may" or "will" occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. For-ward-looking information includes, but is not limited to statements regarding: the Toronto Wolfpack’s position and role in the CBD market; the Toronto Wolfpack’s goal of Super League promotion; the Toronto Wolfpack’s go-to-market strategy; the effectiveness of the Toronto Wolfpack and HowlBrands products; political changes in Canada and internationally, future legislative and regulatory developments involving cannabis in Canada and internationally, Toronto Wolfpack’s ability to secure distribution channels in international jurisdictions, competition and other risks affecting Toronto Wolfpack in particular and the cannabis industry generally. 
The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, Toronto Wolfpack and HowlBrands do not undertake any obligation to publicly update or revise any forward- looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/37cc0fbe-ca83-49eb-a3a4-5b0220e1a4a3

http://www.globenewswire.com/NewsRoom/AttachmentNg/a548879a-55de-4937-b9c8-c3af581bffc9

http://www.globenewswire.com/NewsRoom/AttachmentNg/40bec302-ac69-48ad-99f4-80917c0638da

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation29.5.2020 12:45:00 CESTPress release

Piqray (alpelisib) in combination with fulvestrant will become first and only targeted treatment for advanced breast cancer patients whose tumors harbor a PIK3CA mutation in Europe Phase III trial showed Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months) in this patient population, compared to fulvestrant alone PIK3CA mutations affect approximately 40% of HR+/HER2- advanced breast cancer patients and are linked to cancer growth and a poorer disease prognosis in the metastatic setting The digital press release with multimedia content can be accessed here: Basel, May 29, 2020 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of Piqray® (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metast

Bavarian Nordic meddeler at Janssen har modtaget positiv anbefaling fra det Europæiske Lægemiddelagentur vedrørende godkendelse af ebolavaccinen29.5.2020 12:42:08 CESTpressemeddelelse

KØBENHAVN, Danmark, 29. maj 2020 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at selskabets strategiske partner, Janssen Pharmaceutical Companies of Johnson & Johnson, har modtaget en positiv anbefaling fra udvalget for humanmedicinske lægemidler (CHMP) under det Europæiske Lægemiddelagentur (EMA) for vaccinen mod ebola, forårsaget af Zaire ebolavirussen. Der blev indsendt to ansøgninger med henblik på godkendelse af de to komponenter, der indgår i vaccinen; Ad26.ZEBOV, der er baseret på Janssen AdVac® teknologi, og MVA-BN® Filo, der er baseret på Bavarian Nordics MVA-BN® teknologi, og som gives ca. 8 uger efter den første dosis. Formålet med de to doser er at fremkalde langvarig immunitet mod ebolavirussen. Vaccinen er specifikt udformet til forebyggende vaccination i lande, der er i risiko for ebolaudbrud samt for andre risikogrupper, såsom sundhedsarbejdere, BSL4 laboratoriearbejdere, militærpersonale indsat fra andre lande, lufthavnspersonale og besøgende i højrisikolande. Jan

Bavarian Nordic Announces that Janssen has Received Positive CHMP Opinion for its Investigational Preventative Ebola Vaccine Regimen29.5.2020 12:42:08 CESTPress release

COPENHAGEN, Denmark, May 29, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that its strategic partner Janssen Pharmaceutical Companies of Johnson & Johnson has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its investigational Ebola vaccine regimen for the prevention of the Ebola Virus Disease caused by the Zaire ebolavirus species. Two Marketing Authorisation Applications (MAAs) were submitted to the EMA in support of the vaccines in the two-dose regimen, which includes Ad26.ZEBOV as the first dose, based on Janssen’s proprietary AdVac® viral vector technology, and MVA-BN Filo as the second dose, based on Bavarian Nordic’s MVA-BN® technology, administered approximately eight weeks later. The goal of this two-dose approach is to induce long-term immunity against Ebola Virus Disease. The regimen is specifically designed to support preventative vaccination in countries that are at

CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer29.5.2020 12:03:00 CESTPress release

·Rozlytrek has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy in Europe Basel, 29 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion under conditional marketing authorisation for Rozlytrek® (entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory treatment options. The CHMP has also recommended Rozlytrek for the treatment of adults with ROS1-positive, advanced non-small cell lung cancer (NSCLC) not previously treated with RO

RESULT OF RIKSBANK REVERSED AUCTION SEK BONDS MAY 29, 202029.5.2020 10:09:32 CESTPress release

Auction date2020-05-29Loan1061Coupon0.75 %ISIN-codeSE0011281922Maturity2029-11-12Tendered volume, SEK mln1,000 +/- 250Volume offered, SEK mln3,825Volume bought, SEK mln1,000Number of bids17Number of accepted bids2Average yield-0.040 %Lowest accepted yield-0.040 %Highest yield-0.039 %% accepted at lowest yield 90.00 Auction date 2020-05-29 Loan 1062 Coupon 0.125 % ISIN-code SE0013935319 Maturity 2031-05-12 Tendered volume, SEK mln 1,000 +/- 250 Volume offered, SEK mln 4,150 Volume bought, SEK mln 1,000 Number of bids 15 Number of accepted bids 4 Average yield 0.093 % Lowest accepted yield 0.089 % Highest yield 0.096 % % accepted at lowest yield 100.00